当前位置： SCI文献检索 > JOURNAL OF KOREAN MEDICAL SCIENCE期刊下所有文献 > Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation.

Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation.

Abstract：

BACKGROUND:Hepatocellular carcinoma (HCC) recurrence and development of de novo malignancy (DNM) after liver transplantation (LT) are the major causes of late recipient death. METHODS:We analyzed the incidence of extrahepatic DNM following living donor LT according to the status of pretransplant hepatic malignancy. We selected 2,076 adult patients who underwent primary LDLT during 7 years from January 2010 to December 2016. RESULTS:The pretransplant hepatic malignancy group (n = 1,012) showed 45 cases (4.4%) of the following extrahepatic DNMs: posttransplant lymphoproliferative disease (PTLD) in 10; lung cancer in 10; stomach cancer in 6; colorectal cancer in 5; urinary bladder cancer in 3; and other cancers in 11. The pretransplant no hepatic malignancy group (n = 1,064) showed 25 cases (2.3%) of the following extrahepatic DNMs: colorectal cancer in 3; stomach cancer in 3; leukemia in 3; lung cancer in 3; PTLD in 2; prostate cancer in 2; and other cancers in 9. Incidences of extrahepatic DNM in the pretransplant hepatic malignancy and no hepatic malignancy groups were as follows: 1.1% and 0.5% at 1 year, 3.2% and 2.0% at 3 years, 4.6% and 2.5% at 5 years, and 5.4% and 2.8% at 8 years, respectively (P = 0.006). Their overall patient survival rates were as follows: 97.3% and 97.2% at 1 year, 91.6% and 95.9% at 3 years, 89.8% and 95.4% at 5 years, and 89.2% and 95.4% at 8 years, respectively (P < 0.001). Pretransplant hepatic malignancy was the only significant risk factor for posttransplant extrahepatic DNM. CONCLUSION:Our results suggest that patients who had pretransplant hepatic malignancy be followed up more strictly because they have a potential risk of primary hepatic malignancy recurrence as well as a higher risk of extrahepatic DNM than patients without pretransplant hepatic malignancy.

journal_name

J Korean Med Sci

journal_title

Journal of Korean medical science

authors

Park GC,Hwang S,Ahn CS,Kim KH,Moon DB,Ha TY,Song GW,Jung DH,Yoon YI,Cho HD,Kwon JH,Chung YK,Kang SH,Choi JU,Jung IJ,Lee SG

doi

10.3346/jkms.2020.35.e69

subject

Has Abstract

pub_date

2020-03-23 00:00:00

pages

e69

issue

eissn

1011-8934

issn

1598-6357

pii

35.e69

journal_volume

pub_type

杂志文章

在线工具

Pretransplant Hepatic Malignancy Increases Risk of De Novo Malignancy after Liver Transplantation.